FDA priority review for Algeta and Bayer's prostate cancer agent radium-223
German pharma major Bayer (BAYN: DE) has received notification from the US Food and Drug Administration granting priority review of the New Drug Application filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223), formerly referred to as Alpharadin.
The drug is licensed from Norway’s Algeta (OSE: ALGETA), which will co-promote radium-223 with Bayer in the USA, and is eligible for milestones as well as royalties on Bayer’s sales outside the USA. The US application is under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze